Anecortave acetate: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 4: | Line 4: | ||
File:Anecortave_synth.png|Synthesis pathway of Anecortave acetate | File:Anecortave_synth.png|Synthesis pathway of Anecortave acetate | ||
</gallery> | </gallery> | ||
==Anecortave Acetate== | |||
'''Anecortave acetate''' is a synthetic [[corticosteroid]] derivative that has been investigated for its potential use in the treatment of [[ocular]] conditions, particularly those involving [[neovascularization]]. It is a derivative of [[cortisol]] and is chemically related to other corticosteroids, but it has been modified to reduce its glucocorticoid activity while retaining its anti-angiogenic properties. | |||
===Mechanism of Action=== | |||
Anecortave acetate functions primarily as an anti-angiogenic agent. It inhibits the formation of new blood vessels, a process known as [[angiogenesis]], which is a critical factor in the progression of several ocular diseases. The drug achieves this by interfering with the signaling pathways that promote the proliferation and migration of [[endothelial cells]], which are essential for new blood vessel formation. | |||
===Clinical Applications=== | |||
Anecortave acetate has been studied for its potential use in treating [[age-related macular degeneration]] (AMD), a leading cause of vision loss in the elderly. In AMD, abnormal blood vessels grow under the [[retina]], leading to [[vision impairment]]. By inhibiting angiogenesis, anecortave acetate aims to prevent the progression of this condition. | |||
===Administration=== | |||
The drug is typically administered as a periocular injection, which involves delivering the medication to the area surrounding the eye. This method allows for localized treatment, minimizing systemic exposure and potential side effects associated with corticosteroids. | |||
===Research and Development=== | |||
While anecortave acetate showed promise in early clinical trials, subsequent studies yielded mixed results regarding its efficacy compared to other treatments, such as [[anti-VEGF]] therapies. As a result, its development has been limited, and it is not widely used in clinical practice. | |||
==Related Pages== | |||
* [[Corticosteroid]] | |||
* [[Angiogenesis]] | |||
* [[Age-related macular degeneration]] | |||
* [[Anti-VEGF therapy]] | |||
{{Corticosteroids}} | |||
{{Ophthalmology}} | |||
[[Category:Corticosteroids]] | |||
[[Category:Ophthalmology]] | |||
[[Category:Anti-angiogenic agents]] | |||
Latest revision as of 00:39, 19 February 2025
Anecortave acetate[edit]
-
Chemical structure of Anecortave acetate -
Synthesis pathway of Anecortave acetate
Anecortave Acetate[edit]
Anecortave acetate is a synthetic corticosteroid derivative that has been investigated for its potential use in the treatment of ocular conditions, particularly those involving neovascularization. It is a derivative of cortisol and is chemically related to other corticosteroids, but it has been modified to reduce its glucocorticoid activity while retaining its anti-angiogenic properties.
Mechanism of Action[edit]
Anecortave acetate functions primarily as an anti-angiogenic agent. It inhibits the formation of new blood vessels, a process known as angiogenesis, which is a critical factor in the progression of several ocular diseases. The drug achieves this by interfering with the signaling pathways that promote the proliferation and migration of endothelial cells, which are essential for new blood vessel formation.
Clinical Applications[edit]
Anecortave acetate has been studied for its potential use in treating age-related macular degeneration (AMD), a leading cause of vision loss in the elderly. In AMD, abnormal blood vessels grow under the retina, leading to vision impairment. By inhibiting angiogenesis, anecortave acetate aims to prevent the progression of this condition.
Administration[edit]
The drug is typically administered as a periocular injection, which involves delivering the medication to the area surrounding the eye. This method allows for localized treatment, minimizing systemic exposure and potential side effects associated with corticosteroids.
Research and Development[edit]
While anecortave acetate showed promise in early clinical trials, subsequent studies yielded mixed results regarding its efficacy compared to other treatments, such as anti-VEGF therapies. As a result, its development has been limited, and it is not widely used in clinical practice.
Related Pages[edit]
| Mineralocorticoids and antimineralocorticoids (H02) | ||||||
|---|---|---|---|---|---|---|
|
This article is a ophthalmology stub. You can help WikiMD by expanding it!
